Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
ASCO 2023 - Breast Cancer
Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Women's Health
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
ASCO 2023 - Breast Cancer
Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Women's Health
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
2020 Year in Review - Biosimilars
Safety and Clinical Evaluation of Trastuzumab-dttb + Pertuzumab in Patients with HER2-Positive Breast Cancer
Biosimilars
2020 Year in Review - Biosimilars
Real-world data indicate the efficacy and safety profile of the biosimilar trastuzumab-dttb + pertuzumab was consistent with that previously reported for trastuzumab reference + pertuzumab in patients with HER2-positive breast cancer.
Read More ›
Page 4 of 4
1
2
3
4